TLR9 and malaria: A new formulation of the BK-SE36 vaccine candidate with a Toll-like receptor 9 stimulating adjuvant, CpG-ODN (K3) showed promising safety and immunogenicity results in malaria-naïve Japanese adults [34] and more recently in malaria-exposed adults and children in Burkina Faso.